#1 Clinical Trials Search in Europe

Fostemsavir

Fostemsavir is a novel drug being studied in clinical trials for the treatment of HIV-1 infection, particularly in patients with multidrug-resistant virus or those who have failed other antiretroviral therapies. This article explores the use of Fostemsavir in various clinical trials, its potential benefits, and its impact on HIV treatment strategies.

Table of Contents

What is Fostemsavir?

Fostemsavir, also known by its brand name Rukobia, is a new medication designed to treat Human Immunodeficiency Virus 1 (HIV-1) infections[2]. It’s particularly important for patients who have developed resistance to multiple HIV drugs and are struggling to find an effective treatment[2]. Fostemsavir represents a breakthrough in HIV treatment as it’s the first of its kind in a new class of drugs called attachment inhibitors[4].

How Fostemsavir Works

Fostemsavir works in a unique way compared to other HIV medications. It’s actually a prodrug, which means it’s inactive when you take it, but your body converts it into an active form called temsavir[3]. Temsavir then attaches to a part of the HIV virus called gp120, preventing the virus from attaching to and infecting healthy immune cells (specifically, CD4+ T-cells)[4].

This mechanism is different from other HIV drugs because it doesn’t interfere with the virus once it’s inside the cell. Instead, it stops the virus from entering cells in the first place. This unique approach may help explain why fostemsavir seems to be effective even in patients who have developed resistance to other HIV medications[4].

Who Can Benefit from Fostemsavir?

Fostemsavir is primarily intended for people living with HIV who have tried multiple other HIV medications but haven’t been able to get their virus under control. These patients are often referred to as “heavily treatment-experienced” (HTE)[2]. Specifically, fostemsavir may be beneficial for:

  • Adults with multidrug-resistant HIV-1 infection who are experiencing treatment failure with their current antiretroviral therapy[2].
  • Patients who have confirmed HIV-1 RNA levels of 1000 copies/mL or higher, indicating that their current treatment isn’t effectively suppressing the virus[2].
  • People who are unable to create an effective treatment regimen with other available antiretroviral drugs[2].

Additionally, research is being conducted to see if fostemsavir could help patients who have achieved viral suppression but haven’t seen their CD4+ T-cell counts recover as expected. These patients are known as “immunologic non-responders” (INRs)[4].

Clinical Trials and Research

Several clinical trials have been conducted or are ongoing to evaluate the effectiveness and safety of fostemsavir:

  • The BRIGHTE study was a key trial that led to the FDA approval of fostemsavir. It showed that adding fostemsavir to an optimized background regimen helped achieve viral suppression in 60% of patients with 1-2 fully active antiretroviral classes remaining, and 37% of patients with no fully active classes remaining after 96 weeks[4].
  • The SHIELD study is investigating the use of fostemsavir in children and adolescents with HIV who have dual- or triple-class antiretroviral resistance[1].
  • The RECOVER study is looking at whether adding fostemsavir to a stable HIV regimen can improve immune function in patients who have achieved viral suppression but haven’t seen their CD4+ T-cell counts recover as expected[4].

Dosage and Administration

Fostemsavir is typically administered as follows:

  • The standard dose is 600 mg twice daily[2].
  • It’s taken orally in the form of extended-release tablets[2].
  • Fostemsavir is used in combination with other antiretroviral medications, not as a standalone treatment[1].

It’s important to note that the exact dosage and administration may vary based on individual patient factors, and should always be determined by a healthcare provider.

Safety and Side Effects

Clinical trials have shown that fostemsavir is generally well-tolerated[4]. However, like all medications, it can cause side effects. Common side effects and safety considerations include:

  • Potential for adverse events (AEs) and serious adverse events (SAEs)[3].
  • Possible changes in vital signs and clinical laboratory parameters[3].

The exact nature and frequency of side effects are still being studied. Patients should report any unusual symptoms or side effects to their healthcare provider.

Impact on Quality of Life

Research is ongoing to understand how fostemsavir affects patients’ quality of life. Studies are looking at:

  • Changes in health-related quality of life scores[4].
  • Changes in HIV or antiretroviral therapy-related symptoms[4].
  • Patient satisfaction with treatment[4].

These studies aim to provide a more comprehensive understanding of how fostemsavir affects patients beyond just controlling the virus.

Aspect Details
Drug Name Fostemsavir (FTR)
Drug Class Attachment inhibitor
Target Population HIV-1 infected individuals with multidrug-resistant virus or treatment failure
Administration Oral tablets, typically 600 mg twice daily
Key Clinical Trials SHIELD (Penta22), BRIGHTE, RECOVER
Primary Outcomes Safety, pharmacokinetics, antiviral activity, CD4+ T-cell count changes
Secondary Outcomes Viral suppression rates, adverse events, quality of life, treatment satisfaction
Special Populations Children, adolescents, heavily treatment-experienced patients
Potential Benefits Improved immune reconstitution, viral suppression in resistant cases

FAQ

  • What is Fostemsavir? Fostemsavir is a new type of HIV medication called an attachment inhibitor. It works by preventing the HIV virus from attaching to and entering immune cells, thus helping to control the infection.
  • Who might benefit from Fostemsavir? Fostemsavir is primarily being studied for people with HIV who have developed resistance to multiple other HIV medications or who are experiencing treatment failure with their current antiretroviral therapy.
  • How is Fostemsavir administered? Fostemsavir is typically administered as oral tablets, usually 600 mg twice daily, in combination with other antiretroviral medications as part of an optimized background therapy.
  • What are the main goals of Fostemsavir clinical trials? The clinical trials aim to evaluate the safety, effectiveness, and tolerability of Fostemsavir. They also assess its impact on viral load reduction, CD4+ T-cell count improvement, and overall immune system recovery in HIV patients.
  • Are there any special considerations for Fostemsavir use in children and adolescents? Yes, some trials are specifically designed to evaluate the safety, pharmacokinetics, and effectiveness of Fostemsavir in HIV-1 infected children and adolescents who have limited treatment options due to resistance to other antiretroviral drugs.

Ongoing Clinical Trials on Fostemsavir

  • Study on the Safety and Effectiveness of Fostemsavir for Patients with Multi-drug Resistant HIV-1 Who Have Had Extensive Previous Treatments

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Romania

Glossary

  • Fostemsavir (FTR): A prodrug that is converted in the body to temsavir, which is an attachment inhibitor used to treat HIV-1 infection.
  • Temsavir (TMR): The active form of fostemsavir, which works by binding to the HIV virus's gp120 protein, preventing it from attaching to CD4+ T-cells.
  • CD4+ T-cells: A type of white blood cell that plays a crucial role in the immune system and is targeted by HIV.
  • Viral load: The amount of HIV virus present in a person's blood, often measured in copies per milliliter.
  • Antiretroviral therapy (ART): A combination of medications used to treat HIV infection by suppressing the virus and slowing its progression.
  • Multidrug-resistant HIV: A form of HIV that has developed resistance to multiple antiretroviral medications, making treatment more challenging.
  • Optimized Background Therapy (OBT): A personalized combination of antiretroviral drugs chosen based on a patient's treatment history and resistance profile.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Virologic failure: When antiretroviral therapy fails to suppress and sustain a person's viral load to less than 200 copies per mL.
  • Immunologic non-responders (INRs): HIV patients who achieve viral suppression with antiretroviral therapy but fail to experience optimal CD4+ T-cell count recovery.

References

  1. https://clinicaltrials.gov/study/NCT04648280
  2. https://clinicaltrials.gov/study/NCT04233047
  3. https://clinicaltrials.gov/study/NCT04757974
  4. https://clinicaltrials.gov/study/NCT05220358